Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-02

FDA Approved: EZETIMIBE AND SIMVASTATIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

View source ↗

Summary

FDA approved a supplemental application for the ezetimibe and simvastatin combination product. This action updates the product's labeling following Glenmark's s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EZETIMIBE AND SIMVASTATIN (ezetimibe and simvastatin)

Snippet

SUPPL AP for EZETIMIBE AND SIMVASTATIN (EZETIMIBE AND SIMVASTATIN)